The successful use of pembrolizumab in a renal transplant recipient with metastatic melanoma

We report a case in which a renal transplant recipient with metastatic melanoma had an excellent response to treatment with second line programmed cell death protein 1 (PD-1) inhibitor therapy, pembrolizumab. Acute cellular allograft rejection on initiation of PD-1 inhibitor was successfully reversed with methylprednisolone. By converting the patient to sirolimus and giving predose prednisolone, pembrolizumab was continued with stable renal function and an excellent oncological response. This case supports the efficacy of PD-1 inhibitors in patients who are chronically immunosuppressed, and suggests an approach to maintain transplant function.

[1]  M. Suarez‐Almazor,et al.  Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature , 2019, Journal of Immunotherapy for Cancer.

[2]  L. E. Aguirre,et al.  Immune Checkpoint Inhibitors and the Risk of Allograft Rejection: A Comprehensive Analysis on an Emerging Issue. , 2018, The oncologist.

[3]  Gregory Riely,et al.  Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Perazella,et al.  Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future. , 2018, Journal of the American Society of Nephrology : JASN.

[5]  S. Jang,et al.  Complete Tumor Response to Pembrolizumab and Allograft Preservation in Renal Allograft Recipient on Immunosuppressive Therapy. , 2017, Journal of oncology practice.

[6]  H. Lai,et al.  Tumor regression and preservation of graft function after combination with anti-PD-1 immunotherapy without immunosuppressant titration. , 2017 .

[7]  N. Karanth,et al.  Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report , 2017, Journal of Medical Case Reports.

[8]  W. Chon,et al.  Renal allograft granulomatous interstitial nephritis: observations of an uncommon injury pattern in 22 transplant recipients , 2017, Clinical kidney journal.

[9]  K. Jhaveri,et al.  Preserved Renal-Allograft Function and the PD-1 Pathway Inhibitor Nivolumab. , 2017, The New England journal of medicine.

[10]  J. Taube,et al.  Tumor Regression and Allograft Rejection after Administration of Anti-PD-1. , 2016, The New England journal of medicine.

[11]  E. Woodle,et al.  Drug-induced acute interstitial nephritis in renal allografts: histopathologic features and clinical course in six patients. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.